Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation

Journal of Women's Health

Volumn 15, Issue 1, 2006, Pages 35-44

  Grodstein, Francine ^a,b   Manson, Joann E ^a,b   Stampfer, Meir J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CONJUGATED ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; ONSET AGE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; AGE OF ONSET; AGED; AGING; CONFIDENCE INTERVALS; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENOPAUSE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; WOMEN'S HEALTH;

EID: 32044435429     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.35     Document Type: Article

References (22)

1. Hu FB, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: The epidemiologic evidence. Am J Cardiol 2002;90:26F.
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523.
3. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288-321.
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701.
5. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645.
6. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605.
7. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933.
8. World Health Organization. IHD register: Report of the Fifth Working Group. Copenhagen, Denmark: World Health Organization, 1971.
9. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol 1984;119:837.
10. Willett WC, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983;117:651.
11. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987;126:319.
12. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Washington, DC: Government Printing Office, 1979 (NIH publication No. (PHS)79-1649).
13. Rothman KJ. Modern epidemiology. Boston, MA: Little, Brown, and Co., 1986:153.
14. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13.
15. Koh KK, Shin MS, Sakuma I, et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:1516.
16. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991;338:774.
17. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466.
18. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Steen S. The direct antiatherogenic effect of estrogen is present, absent or reversed, depending on the state of the arterial endothelium: A time course study in cholesterol-clamped rabbits. Circulation 1999;100: 1727.
19. Brownley KA, Hinderliter AL, West SG, et al. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: Differences associated with years since menopause. Am J Obstet Gynecol 2004;190:1052.
20. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673.
21. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983.
22. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047.